Compare WALD & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WALD | TNXP |
|---|---|---|
| Founded | 1988 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.8M | 231.3M |
| IPO Year | 2021 | N/A |
| Metric | WALD | TNXP |
|---|---|---|
| Price | $1.93 | $17.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 1 |
| Target Price | $4.76 | ★ $70.00 |
| AVG Volume (30 Days) | 169.5K | ★ 639.5K |
| Earning Date | 11-24-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $274,560,000.00 | $10,299,000.00 |
| Revenue This Year | $4.61 | $14.79 |
| Revenue Next Year | $11.22 | $933.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.22 | N/A |
| 52 Week Low | $1.48 | $6.76 |
| 52 Week High | $4.10 | $72.00 |
| Indicator | WALD | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 41.56 | 43.38 |
| Support Level | $1.73 | $17.71 |
| Resistance Level | $2.01 | $19.35 |
| Average True Range (ATR) | 0.16 | 1.34 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 25.33 | 37.55 |
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.